Your browser does not support JavaScript!

Matières premières

351 entreprises et organismes intervenants dans le domaine 'Matières premières', classés par activité.

Rejoignez la communauté
MERCK MILLIPORE
est cité dans une actualité de Labiotech.eu
Il y a 4 jours

First Ever Ebola Vaccine Gets Conditional EU Approval

Il y a 1 semaine
The big pharma company Merck has won a conditional marketing authorization from the European Commission for the Ebola vaccine Ervebo, the first to be approved. Ervebo has been approved in Europe to...
www.labiotech.eu
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 1 semaine

EuroBiotech Report—AstraZeneca's lupus filing, Roche SMA data, Kiadis cuts, Genfit and Merck

Il y a 1 semaine
In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot....
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 2 semaines

Merck, BMS chip into PathAI’s series B, bringing total to $75M

Il y a 2 semaines
Seven months after banking $60 million, PathAI is at it again. Bristol-Myers Squibb and Merck Global Health Innovation Fund is adding $15 million to the digital pathology player’s series B....
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 2 semaines

Merck taps Promega for new Keytruda microsatellite instability diagnostic

Il y a 2 semaines
Merck will work with Promega to develop the biological analysis company’s microsatellite instability technology into an official, on-label companion diagnostic for its Keytruda immunotherapy in solid...
www.fiercebiotech.com
ABBOTT
est cité dans une actualité de FierceBiotech
Il y a 2 semaines

FDA ranks separate recalls from Abbott, Philips as Class I, its most serious

Il y a 2 semaines
The FDA recently labeled two device recalls as Class I, the most serious, after they were launched by Philips and Abbott earlier this year—including the latter’s CentriMag cardiac support system for...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 22/10/2019

After $700M-plus Merck buyout, Tilos CEO Fox lands at Rheos Medicines

Le 21/10/2019
Barbara Fox, Ph.D., is getting right back on the horse. Fresh off Tilos Therapeutics’ $773 million sale to Merck, Fox is taking the helm of another Cambridge, Massachusetts-based company: Rheos...
www.fiercebiotech.com
ABBOTT
est cité dans une actualité de FierceBiotech
Le 16/10/2019

Abbott partners with Omada, Tandem to extend the reach of its FreeStyle Libre CGM

Le 15/10/2019
Abbott has teamed up with Omada Health to offer its FreeStyle Libre continuous glucose monitoring system through the latter’s digital care program for people with type 2 diabetes. Abbott also...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 11/10/2019

EuroBiotech Report—UCB inks $2.5B deal; Oxford spinout; Bayer, Merck and Gilead

Le 10/10/2019
In this week's EuroBiotech Report, UCB inks $2.5 billion Ra takeout, MiroBio raises £27 million and Bayer forms Riken drug discovery pact. ...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de Labiotech.eu
Le 09/10/2019

UK Company and Merck Team Up to Develop Vaccines Based on the Microbiome

Le 08/10/2019
Merck will pay the microbiome company 4D Pharma up to €316.5M to develop vaccines based on delivering live bacteria to the gut. The partners will develop vaccines against three undisclosed conditions....
www.labiotech.eu
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 01/10/2019

ESMO: AbbVie's PARP inhibitor veliparib finally gets a win, but can it compete?

Le 29/09/2019
BARCELONA—Quietly, and without the fanfare of gene and cell therapies, PARP inhibitors from the likes of AstraZeneca, Merck and GlaxoSmithKline/Tesaro have been racking up big trial wins in breast and...
www.fiercebiotech.com
Charger plus d'actualités